As anemia and transfusion dependency are two of the leading adverse prognostic indicators in patients with MF [2–4], and elevated hepcidin is significantly associated with shortened OS in patients with MF [28], the durable survival outcomes observed with extended MMB treatment in the SIMPLIFY studies are potentially linked to MMB’s marked anemia and TI benefits. The gene discussed is HAMP; the disease is anemia.